IM Cannabis Corp. Finalizes Sale of IMC Holdings, Strengthens Financial Position

IM Cannabis Corp. Finalizes the Sale of IMC Holdings

On September 29, 2026, IM Cannabis Corp. announced the successful completion of the much-anticipated sale of IMC Holdings and its European operations. This strategic move reflects the company's ongoing commitment to strengthening its financial status and operational focus within the medical cannabis sector in Israel.

The transaction was facilitated under a definitive share purchase agreement signed on August 16, 2026, between IM Cannabis, Slil.com Holding Ltd., and IMC Holdings. The sale has resulted in an expected enhancement of approximately C$3 million in shareholders’ equity, significantly bolstering the financial foundation of IM Cannabis.

Key Details of the Transaction

As part of the transaction, IMC Holdings underwent a pre-closing reorganization, allowing the Israeli operations to remain with IM Cannabis while transferring all other assets to the buyer, Slil.com. The only material assets retained by IMC Holdings now include its stakes in Adjupharm GmbH, Xinteza API Ltd., and Shiran Societe Anonyme, alongside certain liabilities that are part of the retained obligations following the acquisition.

Following the closure of the transaction, IM Cannabis aims to direct its resources towards optimizing its Israeli medical cannabis operations. The company also hinted at exploring new opportunities to enhance growth and market reach. It is clear that this strategic shift is aligned with the company's objective to streamline operations and improve its overall corporate structure.

Financial Implications and Future Focus

The primary economic impact of the sale is the expected increase in shareholders' equity, which underlines the management’s foresight in addressing the financial difficulties faced by the organization. The leadership has emphasized that the actual accounting implications may differ, but preliminary analyses indicate significant benefits from this operational pivot.

Slil's acquisition came with a consideration of C$3 million already paid to IM Cannabis, alongside the assumption of specific liabilities retained by IMC Holdings. The management team's focus has now pivoted to managing the retained Israeli operations effectively, leveraging existing market data and insights to capitalize on growth opportunities.

Governance and Oversight Measures

To guarantee that the transaction was handled with the utmost diligence, IM Cannabis's board of directors established a special committee comprising only independent directors. Their role was to evaluate the terms of the transaction and offer recommendations to the broader Board. This move ensured that conflicts of interest were minimal, as CEO Oren Shuster declared his interests and refrained from participating in or voting on the transaction's approval.

Conclusion: A New Chapter for IM Cannabis

The completion of this sale marks a significant milestone for IM Cannabis Corp., positioning it to better respond to market needs in Israel’s burgeoning medical cannabis sector. By shifting its strategy and focusing on core operations domestically, IM Cannabis sets the stage for potential growth and increased profitability in the years ahead.

With the cannabis industry evolving rapidly, companies like IM Cannabis must adapt and forge strategic partnerships that align with their long-term goals. The sale of IMC Holdings is not just a financial maneuver but also a testament to IM Cannabis's commitment to providing high-quality medical cannabis products while enhancing shareholder value.